For about three decades, active surveillance (AS) has been the preferred management for favorable-risk prostate cancer (PC) and has traditionally included confirmatory biopsy to address any under sampling at diagnosis. Recent guidelines, however, have suggested that magnetic resonance imaging (MRI) might replace confirmatory biopsy to do that. A new study led by the San […]
Source